OCUL
Ocular Therapeutix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.64
+0.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.4x
Market Cap
$2.34B
MomentumView details →
1D Return
+0.00%
YTD Return
−11.80%
RSI (14)
57.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.4x
Market Cap
$2.34B
RSI (14)
57.0
MomentumView details →
1D Return
+0.00%
YTD Return
−11.80%
SummaryUpdated Jun 1, 2026
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company founded in 2006 and headquartered in Bedford, Massachusetts. The company specializes in developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel-based formulation technology. Since going public in 2014, Ocular Therapeutix has evolved from a clinical-stage company into a commercial organization with marketed products and a robust pipeline of sustained-release drug delivery systems for various ocular conditions.
Similar companies
Latest newsMore news →
Ocular Therapeutix reported a second-quarter net loss of $0.35 per share, beating the Zacks Consensus Estimate of a $0.40 loss and improving from a $0.39 loss a year earlier.33d agoOcular Therapeutix granted inducement equity awards to new SVP Kelley Allison as a material inducement for her employment acceptance.74d agoOcular Therapeutix, Inc. appointed Jason S. Robins as Chief Financial Officer effective June 10, 2026.85d ago